Myeloma research group
21 – 40 of 46
- show: 20
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2019
-
Mark
Aspects of Phagocyte Function in Multiple Myeloma
(
- Thesis › Doctoral thesis (compilation)
-
Mark
All-oral ixazomib, cyclophosphamide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma
(
- Contribution to journal › Article
-
Mark
Transcriptome-wide association study of multiple myeloma identifies candidate susceptibility genes
(
- Contribution to journal › Article
-
Mark
Sequence variation at the MTHFD1L-AKAP12 and FOPNL loci does not influence multiple myeloma survival in Sweden
(
- Contribution to journal › Letter
- 2018
-
Mark
Genetic correlation between multiple myeloma and chronic lymphocytic leukaemia provides evidence for shared aetiology
(
- Contribution to journal › Article
-
Mark
Bone marrow eosinophils in plasma cell disorders
(
- Contribution to journal › Article
-
Mark
Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma
(
- Contribution to journal › Article
-
Mark
The multiple myeloma risk allele at 5q15 lowers ELL2 expression and increases ribosomal gene expression
(
- Contribution to journal › Article
- 2017
-
Mark
Identification of sequence variants influencing immunoglobulin levels
(
- Contribution to journal › Article
-
Mark
A single-arm, open-label, phase 2 clinical trial evaluating disease response following treatment with BI-505, a human anti-intercellular adhesion molecule-1 monoclonal antibody, in patients with smoldering multiple myeloma
(
- Contribution to journal › Article
-
Mark
Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone : A pooled analysis
(
- Contribution to journal › Article
-
Mark
A single nucleotide polymorphism in the NCF1 gene leading to reduced oxidative burst is associated with systemic lupus erythematosus
(
- Contribution to journal › Article
-
Mark
Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors : a multicenter IMWG study
(
- Contribution to journal › Article
-
Mark
Direct evidence for a polygenic etiology in familial multiple myeloma
(
- Contribution to journal › Article
- 2016
-
Mark
Phagocyte Function Decreases after High-Dose Treatment with Melphalan and Autologous Stem Cell Transplantation in Patients with Multiple Myeloma.
(
- Contribution to journal › Article
-
Mark
Oral Ixazomib, lenalidomide, and dexamethasone for multiple myeloma
(
- Contribution to journal › Article
-
Mark
Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma.
(
- Contribution to journal › Article
- 2015
-
Mark
Antagonistic Human FcγRIIB (CD32B) Antibodies Have Anti-Tumor Activity and Overcome Resistance to Antibody Therapy In Vivo.
(
- Contribution to journal › Article
-
Mark
A phase 1 dose-escalation study of antibody BI-505 in relapsed/refractory multiple myeloma.
(
- Contribution to journal › Article
-
Mark
Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma.
(
- Contribution to journal › Article